Osmetech Files for US IPO; Creates US Parent

The British molecular diagnostics firm intends to raise around $40 million in a US IPO and will be based in the US as a wholly-owned subsidiary of GenMark Diagnostics.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories